Douglas Miehm
Stock Analyst at RBC Capital
(3.02)
# 1,209
Out of 5,182 analysts
60
Total ratings
48.89%
Success rate
0.35%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNKD MannKind | Downgrades: Sector Perform | $7.5 → $3.5 | $2.50 | +40.00% | 5 | Feb 27, 2026 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $234 → $235 | $199.59 | +17.74% | 8 | Dec 10, 2025 | |
| BLCO Bausch + Lomb | Maintains: Outperform | $17 → $19 | $16.49 | +15.22% | 14 | Nov 14, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Sector Perform | $9 → $15 | $15.61 | -3.91% | 11 | Nov 5, 2025 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $8.5 → $10 | $5.35 | +86.92% | 21 | May 2, 2025 | |
| ONCY Oncolytics Biotech | Maintains: Outperform | $6 → $5 | $0.96 | +420.67% | 1 | Mar 10, 2025 |
MannKind
Feb 27, 2026
Downgrades: Sector Perform
Price Target: $7.5 → $3.5
Current: $2.50
Upside: +40.00%
Ligand Pharmaceuticals
Dec 10, 2025
Maintains: Outperform
Price Target: $234 → $235
Current: $199.59
Upside: +17.74%
Bausch + Lomb
Nov 14, 2025
Maintains: Outperform
Price Target: $17 → $19
Current: $16.49
Upside: +15.22%
Aurinia Pharmaceuticals
Nov 5, 2025
Downgrades: Sector Perform
Price Target: $9 → $15
Current: $15.61
Upside: -3.91%
Bausch Health Companies
May 2, 2025
Maintains: Sector Perform
Price Target: $8.5 → $10
Current: $5.35
Upside: +86.92%
Oncolytics Biotech
Mar 10, 2025
Maintains: Outperform
Price Target: $6 → $5
Current: $0.96
Upside: +420.67%